^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FGF3 (Fibroblast growth factor 3)

    i
    Other names: FGF3, Fibroblast Growth Factor 3, V-INT2 Murine Mammary Tumor Virus Integration Site Oncogene Homolog, Murine Mammary Tumor Virus Integration Site 2, Heparin-Binding Growth Factor 3, INT-2 Proto-Oncogene Protein, Proto-Oncogene Int-2, Oncogene INT2, HBGF-3, INT2
    6d
    Comprehensive genomic profiling of vulvar squamous cell carcinoma reveals subtype-specific mutational landscapes. (PubMed, Virchows Arch)
    No significant survival differences were observed between subtypes, although nodal status remained prognostically relevant. These findings refine the molecular taxonomy of VSCC, support the recognition of a third genomic subgroup, and highlight subtype-specific therapeutic targets.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • TERT (Telomerase Reverse Transcriptase) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • FGF3 (Fibroblast growth factor 3) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2)
    |
    TP53 mutation • TMB-H • PIK3CA mutation • TP53 wild-type
    1m
    Molecular characteristics of proximal and distal esophagogastric junction adenocarcinoma. (PubMed, J Thorac Dis)
    Our NGS-based analysis revealed 10 high-frequency mutant genes in EGJA and demonstrated significant molecular differences among EGJA, GCA, and ESCC. These findings support the molecular basis for a distinct TNM staging system for EGJA.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • LRP1B (LDL Receptor Related Protein 1B) • FGF3 (Fibroblast growth factor 3) • CDK6 (Cyclin-dependent kinase 6) • FAT3 (FAT Atypical Cadherin 3) • SPTA1 (Spectrin Alpha) • SFTPA1 (Surfactant Protein A1)
    |
    TP53 mutation
    1m
    Short-term response to alectinib and rapid progression in a lung squamous cell carcinoma patient harboring an EML4-ALK fusion: a case report. (PubMed, Transl Cancer Res)
    The patient received two cycles of nab-paclitaxel and carboplatin, and repeated CT scan showed disease progression. Her treatment was subsequently changed to glumetinib plus iruplinalkib and she died less than one month later...Co-amplification of the multiple genes may be involved in aggressive disease and drug resistance, which should be considered in future clinical trials and clinical management. Early broad-panel next-generation sequencing testing in LUSCC patients who are never-smokers may help guide management for patients who have complex mutational profiles.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • MDM2 (E3 ubiquitin protein ligase) • FGF19 (Fibroblast growth factor 19) • CDK4 (Cyclin-dependent kinase 4) • FGF3 (Fibroblast growth factor 3) • FGF4 (Fibroblast growth factor 4)
    |
    ALK positive • ALK rearrangement • ALK fusion • ALK mutation
    |
    carboplatin • Alecensa (alectinib) • albumin-bound paclitaxel • Qi Xinke (iruplinalkib) • Haiyitan (gumarontinib)
    3ms
    Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Tongji Hospital
    New P2 trial
    |
    CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FGF4 (Fibroblast growth factor 4)
    |
    Keytruda (pembrolizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib)
    4ms
    Characterization of ESR1 alterations in patients with breast and gynecologic cancers. (PubMed, Breast Cancer Res)
    ESR1 alterations were most frequent in HR + /HER2- BC samples and missense mutations were more frequent in metastatic samples, consistent with their role in ET resistance and disease progression. ESR1 alterations co-occurred with therapeutically relevant alterations in other genes that may help inform clinical decision-making. Gynecologic tumors harbored ESR1 alterations that have prognostic and potentially therapeutic relevance.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCND1 (Cyclin D1) • FGF3 (Fibroblast growth factor 3) • CCDC170(Coiled-Coil Domain Containing 170)
    |
    HER-2 amplification • HER-2 negative • HER-2 mutation • ESR1 mutation
    4ms
    A novel oncogenic nonsense mutation of SMARCA4 and genetic characteristic analysis of SMARCA4 (BRG1)-deficient undifferentiated tumor of the bladder. (PubMed, Virchows Arch)
    This suggests that besides SMARCA4 deficiency, alterations in other genes may cooperatively contribute to the tumorigenesis of bladder undifferentiated tumors. These findings provide a reference for subsequent exploration of precise diagnostic and prognostic assessment and treatment strategies for this disease.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • KMT2C (Lysine Methyltransferase 2C) • FGF3 (Fibroblast growth factor 3) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • FGF4 (Fibroblast growth factor 4) • GLI1 (GLI Family Zinc Finger 1) • STAG2 (Stromal Antigen 2) • FLT4 (Fms-related tyrosine kinase 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA3 (EPH receptor A3)
    5ms
    New Gene Signature-Based Prognostic Model for Patients With VEGF-Overexpressing Esophageal Squamous Cell Carcinoma. (PubMed, Biomed Res Int)
    ESCC patients with FAT1, FGF3, FGF12, and FGF19 mutations; advanced M stage; and high neutrophil counts tended to have poorer prognoses. A model based on a four-gene signature effectively predicts the prognosis of ESCC patients.
    Journal • Gene Signature
    |
    VEGFA (Vascular endothelial growth factor A) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FAT1 (FAT atypical cadherin 1)
    8ms
    Prognosis and Failure Patterns of 11q13 Amplified Local Advanced Squamous Cell Carcinoma of the Head and Neck. (PubMed, Cancer Med)
    LA-HNSCC patients with 11q13 amplification exhibited significantly worse DFS and OS compared to wild-type patients. The recurrence pattern in the 11q13 amplification group was primarily characterized by in-field recurrences within the 60 Gy dose.
    Retrospective data • Journal
    |
    CCND1 (Cyclin D1) • FGF3 (Fibroblast growth factor 3)
    8ms
    Predicting response and survival of lung adenocarcinoma under anti-programmed death-1 therapy using biological deep learning. (PubMed, Brief Bioinform)
    Meanwhile, the Low-risk LUAD patients identified by the sBiosNet obtained significant longer overall survival and progression-free survival with anti-PD-1 therapy. In conclusion, the sBiosNet accurately predicts the response and survival of patients on anti-PD-1 therapy to reduce unnecessary treatment in non-responders.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • FGFR4 (Fibroblast growth factor receptor 4) • FGF3 (Fibroblast growth factor 3)
    9ms
    ARID1A-Deficient and 11q13-Amplified Metastatic Pancreatic Cancer Initially Presenting as Retroperitoneal Fibrosis in a Patient with Familial CHEK2 Variant. (PubMed, Diagnostics (Basel))
    Despite identifying these molecular features, poor prognosis was predicted, and no clinically actionable targets were detected, underscoring the need for future therapeutic development. This paradigm highlights molecular profiling as a critical adjunct to conventional diagnostics in maRPF, bridging the gap between histopathological ambiguity and biologically grounded clinical decision-making.
    Journal
    |
    ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • CHEK2 (Checkpoint kinase 2) • FGF4 (Fibroblast growth factor 4) • CA 19-9 (Cancer antigen 19-9)
    |
    ARID1A mutation
    11ms
    Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients. (PubMed, Lung Cancer (Auckl))
    Moreover, SCC could carry canonical NSCLC) activating mutations. Our data suggest that deep molecular analyses resolve tumor heterogeneity and may help with new algorithm-based treatment strategies for SCC.
    Journal • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FGF4 (Fibroblast growth factor 4)
    |
    EGFR mutation • TMB-H • MET mutation
    |
    TruSight Oncology 500 Assay
    1year
    Positive-Negative Selection: The Counterselection Breakthrough that Conventionalized Reverse Genetics in the Mouse. (PubMed, Dev Biol)
    The impact of the work was to revolutionize mouse genetics by enabling the efficient creation of targeted mutations and sophisticated animal models for the analysis of any gene's function in mammalian development and health. These models have been integral to our understanding of fundamental biological processes and disease mechanisms.
    Preclinical • Journal
    |
    FGF3 (Fibroblast growth factor 3)